Oxford Biomedica PLC Total Voting Rights (1873V)
April 03 2023 - 8:19AM
UK Regulatory
TIDMOXB
RNS Number : 1873V
Oxford Biomedica PLC
03 April 2023
Oxford Biomedica
Total Voting Rights
Oxford, UK - 3 April 2023: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company"), a leading gene and cell
therapy group, today announces that in accordance with the FCA's
Disclosure Guidance and Transparency Rule 5.6.1R, the Company's
issued share capital as at the close of business on 31 March 2023
consisted of 96,451,073 ordinary shares of 50 pence each ("Ordinary
Shares"). There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 96,451,073.
The above figure ( 96,451,073) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford Biomedica plc under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector
specialist focused on delivering life changing therapies to
patients.
Oxford Biomedica plc and its subsidiaries (the Group) work
across key viral vector delivery systems including those based on
lentivirus, adeno-associated virus (AAV) and adenovirus, providing
innovative solutions to cell and gene therapy biotechnology and
biopharma companies for their process development, analytical
development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(R)
platform, and is working on programmes from pre-clinical to
commercial stage across a range of therapeutic areas with global
partners.
Oxford Biomedica is based across several locations and
headquartered in Oxfordshire, UK. In 2022, the Group established
Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing
and innovation business, based near Boston, US.
Further information is available at www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAALDEFKDEFA
(END) Dow Jones Newswires
April 03, 2023 08:19 ET (12:19 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Dec 2023 to Dec 2024